This controversy pertains to a number of aspects, including the relative inactivity of ERβ in this particular type of cancer, attributable to the low expression of AP1 (activating factor 1, a heterodimer of Fos and Jun proteins) and NF-κB [109]. The gene discussed is FOS; the disease is cancer.